Company profile
Sana Biotechnology, Inc.
NASDAQ: SANA · Healthcare · Biotechnology
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 33DQ —GM —SS 57
v0.1 · 35/100 weight · pillars only
↑ market scale, workforce scale · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$244.2M
Employees
142
as of 2026-08-10
Market cap
$979.6M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$244.2M-$244.2M2025
Operating income-$250.3M-$250.3M2025
Total assets$416.9M$416.9M2025
Liabilities$256.0M$256.0M2025
Equity$160.9M$160.9M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Sana Biotechnology, Inc.’s financial profile?
Sana Biotechnology, Inc. earned -$244.2M in FY2025 net income.
Peers · Healthcare
Replimune Group, Inc.——Alto Neuroscience, Inc.——Lumexa Imaging Holdings, Inc. Common Stock——Annexon, Inc.——Faeth Therapeutics, Inc.——Aura Biosciences, Inc.——Neighbors
King →Key facts
CEOSteven D. Harr
SectorHealthcare
IndustryBiotechnology
HeadquartersSeattle, WA
ExchangeNASDAQ: SANA
Employees142
IPO date2021-02-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.